Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activityThe invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-N3-(2-(3-fluorophenyl)ethyl)-N-(2-[(2-(4- hydroxy-2-oxo-2,3-dihydro- 1,3-benzothiazol-7-yl)ethyl)amino] ethyl)-beta-alaninamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCRl antagonist; a chemokine antagonist (not CCRl); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PDE inhibitor; a PPAR agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease (for example chronic obstructive pulmonary disease (COPD) or asthma); to certain salts of N-Cyclohexyl-N3-(2-(3-fluorophenyl)ethyl)- N-(2-[(2-(4-hydroxy-2-oxo-2,3-dihydro-l,3-benzothiazol-7-yl)ethyl)amino]ethyl)-beta- alaninamide and to an intermediate useful in the manufacture of this pharmaceutically active substance and salts thereof.Drug products, it comprises the combination of first active component and second active component, and described first active component is n-cyclohexyl-n 3-[2-(3-fluorophenyl) ethyl]-n-(2-{[2-(4-hydroxyl-2-oxo-2,3-dihydro-1,3-benzothiazole-7-yl) ethyl] amino } ethyl)-beta-amino propionic acid amide. or its salt, described second active component is selected from: non-steroidal glucocoricoid receptor (gr receptor) agonist;antioxidant;the ccr1 antagonist;chemokine antagonists (non-ccr1 antagonist);17-hydroxy-11-dehydrocorticosterone;the crth2 antagonist;the dp1 antagonist;the histone deacetylase derivant;the ikk2 inhibitor;the cox inhibitor;lipoxidase inhibitor;ltra;the mpo inhibitor;muscarinic antagonists;the p38 inhibitor;the pde inhibitor;the ppar gamma agonist;protease inhibitor;statins;the thromboxane antagonist;vasodilation; orenac blocker (epithelium sodium channel blockers);condition is that described muscarinic antagonists is not:(r)-3-(1-phenyl-cycloheptane ketonic oxygen base)-1-(pyrazine-2-base carbamyl methyl)-1-nitrogen-bicyclo-[2.2.2] octane x;(r)-3-(1-phenyl-cycloheptane ketonic oxygen base)-1-(pyridazine-3-base carbamyl methyl)-1-nitrogen-bicyclo-[2.2.2] octane x;(r)-3-[1-(3-fluoro-phenyl)-cycloheptane ketonic oxygen base]-1-(pyrazine-2-base carbamyl methyl)-1-nitrogen-bicyclo-[2.2.2] octane x;(r)-3-[1-(3-fluoro-phenyl)-cycloheptane ketonic oxygen base]-1-(isoxazole-3-base carbamyl methyl)-1-nitrogen-bicyclo-[2.2.2] octane x;(r)-3-(1-phenyl-cycloheptane ketonic oxygen base)-1-(pyridine-2-base carbamyl methyl)-1-nitrogen-bicyclo-[2.2.2] octane x;(r)-1-[(5-fluoro-pyridine-2-base carbamyl)-methyl]-3-(1-phenyl-cycloheptane ketonic oxygen base)-1-nitrogen-bicyclo-[2.2.2] octane x;(r)-3-(1-phenyl-cycloheptane ketonic oxygen base)-1-(pyridin-3-yl carbamyl methyl)-1-nitrogen-bicyclo-[2.2.2] octane x; or(r)-1-[(2-methyl-pyridin-4-yl carbamyl)-methyl]-3-(1-phenyl-cycloheptane ketonic oxygen base)-1-nitrogen-bicyclo-[2.2.2] octane x;wherein x represents the anion of medicinal monoacid or polyprotic acid.
베타２－아드레날린수용체 활성의 조절을 위한, ４－히드록시－２－옥소－２,３－디히드로－１,３－벤조티아졸－７－일 화합물을 포함하는 제약 조성물본 발명은 N-시클로헥실-N3-[2-(3-플루오로페닐)에틸]-N-(2-{[2-(4-히드록시-2-옥소-2,3-디히드로-1,3-벤조티아졸-7-일)에틸]아미노}에틸)-β-알라닌아미드 또는 그의 염인 제1 활성 성분, 및 비스테로이드성 글루코코르티코이드 수용체 (GR 수용체) 효능제; 항산화제; CCR1 길항제; 케모카인 길항제 (CCR1이 아님); 코르티코스테로이드; CRTh2 길항제; DP1 길항제; 히스톤 데아세틸라제 유도제; IKK2 억제제; COX 억제제; 리폭시게나제 억제제; 류코트리엔 수용체 길항제; MPO 억제제; 무스카린성 길항제; p38 억제제; PDE 억제제; PPARγ 효능제; 프로테아제 억제제; 스타틴; 트롬복산 길항제; 혈관확장제; 또는 ENAC 차단제 (상피성 나트륨-채널 차단제)로부터 선택되는 제2 활성 성분을 포함하는 제약 생성물, 키트 또는 조성물; 및 호흡기 질환 (예를 들면, 만성 폐쇄성 폐 질환 (COPD) 또는 천식)의 치료에서의 그의 용도; N-시클로헥실-N3-[2-(3-플루오로페닐)에틸]-N-(2-{[2-(4-히드록시-2-옥소-2,3-디히드로-1,3-벤조티아졸-7-일)에틸]아미노}에틸)-β-알라닌아미드의 특정 염; 및 상기 제약 활성 물질 및 그의 염의 제조에 유용한 중간체를 제공한다.N-시클로헥실-N3-[2-(3-플루오로페닐)에틸]-N-(2-{[2-(4-히드록시-2-옥소-2,3-디히드로-1,3-벤조티아졸-7-일)에틸]아미노}에틸)-β-알라닌아미드 또는 그의 염인 제1 활성 성분, 및비스테로이드성 글루코코르티코이드 수용체 (GR 수용체) 효능제;항산화제;CCR1 길항제;케모카인 길항제 (CCR1이 아님);코르티코스테로이드;CRTh2 길항제;DP1 길항제;히스톤 데아세틸라제 유도제;IKK2 억제제;COX 억제제;리폭시게나제 억제제;류코트리엔 수용체 길항제;MPO 억제제;무스카린성 길항제;p38 억제제;PDE 억제제;PPARγ 효능제;프로테아제 억제제;스타틴;트롬복산 길항제;혈관확장제; 또는ENAC 차단제 (상피성 나트륨-채널 차단제)로부터 선택되며, 단 무스카린성 길항제가(R)-3-(1-페닐-시클로헵탄카르보닐옥시)-1-(피라진-2-일카르바모일메틸)-1-아조니아-바이시클로[2.2.2]옥탄 X;(R)-3-(1-페닐-시클로헵탄카르보닐옥시)-1-(피리다진-3-일카르바모일메틸)-1-아조니아-바이시클로[2.2.2]옥탄 X;(R)-3-[1-(3-플루오로-페닐)-시클로헵탄카르보닐옥시]-1-(피라진-2-일카르바모일메틸)-1-아조니아-바이시클로[2.2.2]옥탄 X;(R)-3-[1-(3-플루오로-페닐)-시클로헵탄카르보닐옥시]-1-(이속사졸-3-일카르바모일메틸)-1-아조니아-바이시클로[2.2.2]옥탄 X;(R)-3-(1-페닐-시클로헵탄카르보닐옥시)-1-(피리딘-2-일카르바모일메틸)-1-아조니아-바이시클로[2.2.2]옥탄 X;(R)-1-[(5-플루오로-피리딘-2-일카르바모일)-메틸]-3-(1-페닐-시클로헵탄카르보닐옥시)-1-아조니아-바이시클로[2.2.2]옥탄 X;(R)-3-(1-페닐-시클로헵탄카르보닐옥시)-1-(피리딘-3-일카르바모일메틸)-1-아조니아-바이시클로[2.2.2]옥탄 X; 또는(R)-1-[(2-메틸-피리딘-4-일카르바모일)-메틸]-3-(1-페닐-시클로헵탄카르보닐옥시)-1-아조니아-바이시클로[2.2.2]옥탄 X(여기서, X는 1가 또는 다가 산의 제약상 허용되는 음이온을 나타냄)가 아닌 것인 제2 활성 성분을 조합하여 포함하는 제약 생성물.